Rocket Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 11, 2025 Deadline to file Lead Plaintiff Motion

Core Viewpoint - Rocket Pharmaceuticals is facing a class action lawsuit due to allegations of misleading investors regarding the safety and protocol of its clinical trials for gene therapies [3][4]. Group 1: Company Overview - Rocket Pharmaceuticals is a late-stage biotechnology company focused on developing gene therapies for rare and serious diseases [2]. Group 2: Legal Allegations - The class action lawsuit claims that Rocket Pharmaceuticals provided updates on its Phase 2 trial of RP-A501 for Danon disease while making materially false statements and omitting critical adverse facts about the trial's safety [3]. - The lawsuit alleges that the company was aware of the risk of Serious Adverse Events (SAEs), including patient deaths, but did not fully inform investors [3]. - It is claimed that Rocket Pharmaceuticals amended the trial protocol to include a new immunomodulatory agent without disclosing this change to shareholders [3]. Group 3: Impact of FDA Action - On May 27, 2025, Rocket Pharmaceuticals announced that the U.S. FDA had placed a clinical hold on the RP-A501 Phase 2 trial following the death of a participant treated under the amended protocol, which had not been disclosed to investors [4]. - Following this announcement, Rocket Pharmaceuticals' stock price experienced a decline [4].